|Table of Contents|

Expression of PARP1 in triple negative breast cancer and its relationship with EMT

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 03
Page:
402-405
Research Field:
Publishing date:

Info

Title:
Expression of PARP1 in triple negative breast cancer and its relationship with EMT
Author(s):
Chen Jiqiong; Feng Huiyan; Lin Danli; Huang Jiaqin; Cai Meiting; Li Yurong
Department of Pathology，Dongguan City Zhangmutou Hospital，Guangdong Dongguan 523633，China.
Keywords:
PARP1; triple negative breast cancer; epithelial-mesenchymal transition; E-cadherin; Vimentin
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2020.03.011
Abstract:
Objective：To explore the expression of PARP1 in triple negative breast cancer(TNBC) and its relationship with epithelial-mesenchymal transition(EMT)．Methods：Immunohistochemical assay was performed to detect the expression of PARP1 in 60 cases of TNBC and 30 cases of non-TNBC，and also detect E-cadherin and Vimentin in 60 cases of TNBC.Then the association between PARP1，E-cadherin，Vimentin expressions and clinicopathological factors of TNBC as well as the correlation between among PARP1，E-cadherin，Vimentin expressions were analyzed.Results：The positive expression rate of PARP1 was significantly higher in the TNBC than that in the non-TNBC.The expression of PARP1 in the TNBC was associated with the tumor size，lymphatic metastasis and clinical stage(P<0.05)，but no relationship with age and histological grade was observed．The expression of E-cadherin in the TNBC was negatively co-related to that of PARP1(P<0.05)．In contrast，the expression of Vimentin in the TNBC was positively co-related to that of PARP1(P<0.05)．Conclusion：PARP1 was highly expressed in TNBC.PARP1 may contribute to the onset of EMT in the TNBC by regulating the expression of E-cadherin and Vimentin.

References:

［1］ZHANG XW，ZHONG W，WEI SB，et al.Correlation between triple-negative breast cancer and PARP1 expression：A Meta-analysis［J］.Modern Oncology，2017，25(6)：893-896.［张秀伟，钟文，魏士博，等.三阴性乳腺癌与PARP1表达相关性的Meta分析［J］.现代肿瘤医学，2017，25(6)：893-896.］
［2］Rouleau M，Aubin RA，Poirier GG.Poly(ADP-ribosyl) ated chromatin domains：access granted［J］.Journal of Cell Science，2004，117(6)：815-825.
［3］Andrabi SA，Kim NS，Yu SW，et al.Poly(ADP-ribose) (PAR) polymer is a death signal［J］.PNAS，2006，103(48)：18308-18313.
［4］García S，Carmen C.The role of poly(ADP-ribose) polymerase-1 in rheumatoid arthritis［J］.Mediators of Inflammation，2015（2015）：1-8.
［5］KANAI，Yoshiyuki.Overview on poly(ADP-ribose) immuno-biomedicine and future prospects［J］.Proceedings of the Japan Academy，Series B，2016，92(7)：222-236.
［6］Bo-Hua J，Wei-Lien T，Hsin-Yang L，et al.Poly(ADP-Ribose) polymerase 1：Cellular pluripotency，reprogramming，and tumorogenesis［J］.International Journal of Molecular Sciences，2015，16(12)：15531-15545.
［7］YU L，YANG Q，BI FF.Expression and significance of poly ADP-ribose polymerase-1 in endometrial carcinoma［J］．Modern Oncology，2013，21(4)：849-852．［于蕾，杨清，毕芳芳．PARP-1在子宫内膜样腺癌中的表达［J］.现代肿瘤医学，2013，21(4)：849-852．］
［8］Staibano S，Pepe S，Lo ML，et al.Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region［J］.Human Pathology，2005，36(7)：724-731.
［9］ZHANG CC，WEI W，LIN XY，et al.Expression of PARP-1 in epithelial ovarian cancer and its relationship with epithelial-mesenchymal transition［J］.Chinese Journal of Pathophysiology，2016，32(3)：425-431.［张灿灿，尉蔚，林雪艳，等.上皮性卵巢癌中PARP-1的表达及其与EMT的关系［J］.中国病理生理学杂志，2016，32(3)：425-431.］
［10］Rojo F，Garcíaparra J，Zazo S，et al.Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer［J］.Ann Oncol，2012，23(5)：1156.
［11］Ghabreau L，Roux JP，Frappart PO，et al.Poly(ADP-ribose) polymerase-1，a novel partner of progesterone receptors in endometrial cancer and its precursors［J］.International Journal of Cancer，2004，109(3)：317-321.
［12］LI SY，LI ZY，LI L，et al.The expression PARP1 and P53 in triple-negative breast cancer and its clinical significance［J］．Modern Oncology，2014，22(1)：70-74．［李锁严，李占勇，李蕾，等.PARP-1和P53在三阴性乳腺癌中表达的相关性及临床意义［J］.现代肿瘤医学，2014，22(1)：70-74.］
［13］Ivaska J.Vimentin：Central hub in EMT induction［J］?Small Gtpases，2011，2(1)：51-53.
［14］Pu H，Horbinski C，Hensley PJ，et al.PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis［J］.Carcinogenesis，2014，35(11)：2592-2601.
［15］María Isabel Rodríguez，Andreína PeraltaLeal，O'Valle F，et al.PARP-1 regulates metastatic melanoma through modulation of Vimentin-induced malignant transformation［J］.Plos Genetics，2013，9(6)：e1003531.
［16］LIN XY，LI CY，HOU XM，et al.Expressions of PARP-1 and EMT markers in eutopic and ectpic endometrium of adenomyosis［J］.Journal of Shandong University(Health Sciences)，2017,55(09)：36-40.［林雪艳，李春艳，侯小满，等.PARP-1及EMT标志物在子宫腺肌病在位及异位内膜中的表达［J］.山东大学学报(医学版)，2017,55(09)：36-40.］
［17］Cichon MA，Radisky DC.ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-κB-dependent activation of Snail［J］.Oncotarget，2014，5(9)：2827-2838.
［18］Hassa PO，Covic M，Hasan S，et al.The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function［J］.Journal of Biological Chemistry，2001，276(49)：45588-45597.
［19］Duncan JS，Whittle MC，Nakamura K，et al.Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer［J］.Cell，2012，149(2)：307-321.
［20］Lee J，Galloway R，Grandjean G，et al.Comprehensive two-and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer［J］.Journal of Cancer，2015，6(12)：1306-1319.
［21］Kim S，Lee J，Jeon M，et al.MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells［J］.Tumour Biol，2016，37(4)：4991-4999.
［22］Cohenarmon M，Visochek L，Rozensal D，et al.DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity：A link to histone acetylation［J］.Molecular Cell，2007，25(2)：297-308.

Memo

Memo:
东莞市社会科技发展（一般）项目(编号：2018507150141260)
Last Update: 1900-01-01